Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status
Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Minami, Seigo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013 |
|---|
| Schlagwörter: |
Epidermal growth factor receptor (EGFR) mutation |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation - Garrote, Pedro J. ELSEVIER, 2019, journal of the International Association for the Study of Lung Cancer, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:82 ; year:2013 ; number:2 ; pages:271-275 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.lungcan.2013.07.022 |
|---|
| Katalog-ID: |
ELV021754268 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV021754268 | ||
| 003 | DE-627 | ||
| 005 | 20230623162119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2013.07.022 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013006000003.pica |
| 035 | |a (DE-627)ELV021754268 | ||
| 035 | |a (ELSEVIER)S0169-5002(13)00331-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 100 | 1 | |a Minami, Seigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| 264 | 1 | |c 2013 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. | ||
| 650 | 7 | |a Second-line chemotherapy |2 Elsevier | |
| 650 | 7 | |a Erlotinib |2 Elsevier | |
| 650 | 7 | |a Epidermal growth factor receptor (EGFR) mutation |2 Elsevier | |
| 650 | 7 | |a Non-squamous non-small cell cancer |2 Elsevier | |
| 650 | 7 | |a Phase II |2 Elsevier | |
| 650 | 7 | |a Pemetrexed |2 Elsevier | |
| 700 | 1 | |a Kijima, Takashi |4 oth | |
| 700 | 1 | |a Hamaguchi, Masanari |4 oth | |
| 700 | 1 | |a Nakatani, Takeshi |4 oth | |
| 700 | 1 | |a Koba, Taro |4 oth | |
| 700 | 1 | |a Takahashi, Ryo |4 oth | |
| 700 | 1 | |a Takeuchi, Yoshiko |4 oth | |
| 700 | 1 | |a Kida, Hiroshi |4 oth | |
| 700 | 1 | |a Nagatomo, Izumi |4 oth | |
| 700 | 1 | |a Yamamoto, Suguru |4 oth | |
| 700 | 1 | |a Tachibana, Isao |4 oth | |
| 700 | 1 | |a Komuta, Kiyoshi |4 oth | |
| 700 | 1 | |a Kawase, Ichiro |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Garrote, Pedro J. ELSEVIER |t Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |d 2019 |d journal of the International Association for the Study of Lung Cancer |g Amsterdam [u.a.] |w (DE-627)ELV002331438 |
| 773 | 1 | 8 | |g volume:82 |g year:2013 |g number:2 |g pages:271-275 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2013.07.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2013 |e 2 |h 271-275 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s m sm |
|---|---|
| matchkey_str |
minamiseigokijimatakashihamaguchimasanar:2013----:hsisuyfeerxdlsnemtetroiicmiainhrpfrrtetddacdosumunnmlcllncnewtdcmna |
| hierarchy_sort_str |
2013 |
| publishDate |
2013 |
| allfields |
10.1016/j.lungcan.2013.07.022 doi GBVA2013006000003.pica (DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 Minami, Seigo verfasserin aut Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status 2013 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier Kijima, Takashi oth Hamaguchi, Masanari oth Nakatani, Takeshi oth Koba, Taro oth Takahashi, Ryo oth Takeuchi, Yoshiko oth Kida, Hiroshi oth Nagatomo, Izumi oth Yamamoto, Suguru oth Tachibana, Isao oth Komuta, Kiyoshi oth Kawase, Ichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:82 year:2013 number:2 pages:271-275 extent:5 https://doi.org/10.1016/j.lungcan.2013.07.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 82 2013 2 271-275 5 045F 610 |
| spelling |
10.1016/j.lungcan.2013.07.022 doi GBVA2013006000003.pica (DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 Minami, Seigo verfasserin aut Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status 2013 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier Kijima, Takashi oth Hamaguchi, Masanari oth Nakatani, Takeshi oth Koba, Taro oth Takahashi, Ryo oth Takeuchi, Yoshiko oth Kida, Hiroshi oth Nagatomo, Izumi oth Yamamoto, Suguru oth Tachibana, Isao oth Komuta, Kiyoshi oth Kawase, Ichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:82 year:2013 number:2 pages:271-275 extent:5 https://doi.org/10.1016/j.lungcan.2013.07.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 82 2013 2 271-275 5 045F 610 |
| allfields_unstemmed |
10.1016/j.lungcan.2013.07.022 doi GBVA2013006000003.pica (DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 Minami, Seigo verfasserin aut Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status 2013 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier Kijima, Takashi oth Hamaguchi, Masanari oth Nakatani, Takeshi oth Koba, Taro oth Takahashi, Ryo oth Takeuchi, Yoshiko oth Kida, Hiroshi oth Nagatomo, Izumi oth Yamamoto, Suguru oth Tachibana, Isao oth Komuta, Kiyoshi oth Kawase, Ichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:82 year:2013 number:2 pages:271-275 extent:5 https://doi.org/10.1016/j.lungcan.2013.07.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 82 2013 2 271-275 5 045F 610 |
| allfieldsGer |
10.1016/j.lungcan.2013.07.022 doi GBVA2013006000003.pica (DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 Minami, Seigo verfasserin aut Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status 2013 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier Kijima, Takashi oth Hamaguchi, Masanari oth Nakatani, Takeshi oth Koba, Taro oth Takahashi, Ryo oth Takeuchi, Yoshiko oth Kida, Hiroshi oth Nagatomo, Izumi oth Yamamoto, Suguru oth Tachibana, Isao oth Komuta, Kiyoshi oth Kawase, Ichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:82 year:2013 number:2 pages:271-275 extent:5 https://doi.org/10.1016/j.lungcan.2013.07.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 82 2013 2 271-275 5 045F 610 |
| allfieldsSound |
10.1016/j.lungcan.2013.07.022 doi GBVA2013006000003.pica (DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 Minami, Seigo verfasserin aut Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status 2013 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier Kijima, Takashi oth Hamaguchi, Masanari oth Nakatani, Takeshi oth Koba, Taro oth Takahashi, Ryo oth Takeuchi, Yoshiko oth Kida, Hiroshi oth Nagatomo, Izumi oth Yamamoto, Suguru oth Tachibana, Isao oth Komuta, Kiyoshi oth Kawase, Ichiro oth Enthalten in Elsevier Garrote, Pedro J. ELSEVIER Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation 2019 journal of the International Association for the Study of Lung Cancer Amsterdam [u.a.] (DE-627)ELV002331438 volume:82 year:2013 number:2 pages:271-275 extent:5 https://doi.org/10.1016/j.lungcan.2013.07.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 82 2013 2 271-275 5 045F 610 |
| language |
English |
| source |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:82 year:2013 number:2 pages:271-275 extent:5 |
| sourceStr |
Enthalten in Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation Amsterdam [u.a.] volume:82 year:2013 number:2 pages:271-275 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Second-line chemotherapy Erlotinib Epidermal growth factor receptor (EGFR) mutation Non-squamous non-small cell cancer Phase II Pemetrexed |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| authorswithroles_txt_mv |
Minami, Seigo @@aut@@ Kijima, Takashi @@oth@@ Hamaguchi, Masanari @@oth@@ Nakatani, Takeshi @@oth@@ Koba, Taro @@oth@@ Takahashi, Ryo @@oth@@ Takeuchi, Yoshiko @@oth@@ Kida, Hiroshi @@oth@@ Nagatomo, Izumi @@oth@@ Yamamoto, Suguru @@oth@@ Tachibana, Isao @@oth@@ Komuta, Kiyoshi @@oth@@ Kawase, Ichiro @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002331438 |
| dewey-sort |
3610 |
| id |
ELV021754268 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021754268</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623162119.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2013.07.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013006000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021754268</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(13)00331-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Minami, Seigo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Erlotinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidermal growth factor receptor (EGFR) mutation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-squamous non-small cell cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase II</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pemetrexed</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kijima, Takashi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Masanari</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakatani, Takeshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koba, Taro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Ryo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takeuchi, Yoshiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kida, Hiroshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagatomo, Izumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Suguru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tachibana, Isao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Komuta, Kiyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawase, Ichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:82</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:271-275</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2013.07.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">82</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">271-275</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Minami, Seigo |
| spellingShingle |
Minami, Seigo ddc 610 Elsevier Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| authorStr |
Minami, Seigo |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002331438 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed Elsevier |
| topic |
ddc 610 Elsevier Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed |
| topic_unstemmed |
ddc 610 Elsevier Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed |
| topic_browse |
ddc 610 Elsevier Second-line chemotherapy Elsevier Erlotinib Elsevier Epidermal growth factor receptor (EGFR) mutation Elsevier Non-squamous non-small cell cancer Elsevier Phase II Elsevier Pemetrexed |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t k tk m h mh t n tn t k tk r t rt y t yt h k hk i n in s y sy i t it k k kk i k ik |
| hierarchy_parent_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| hierarchy_parent_id |
ELV002331438 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002331438 |
| title |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| ctrlnum |
(DE-627)ELV021754268 (ELSEVIER)S0169-5002(13)00331-0 |
| title_full |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| author_sort |
Minami, Seigo |
| journal |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| journalStr |
Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
271 |
| author_browse |
Minami, Seigo |
| container_volume |
82 |
| physical |
5 |
| class |
610 610 DE-600 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Minami, Seigo |
| doi_str_mv |
10.1016/j.lungcan.2013.07.022 |
| dewey-full |
610 |
| title_sort |
phase ii study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| title_auth |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| abstract |
Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. |
| abstractGer |
Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. |
| abstract_unstemmed |
Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
2 |
| title_short |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status |
| url |
https://doi.org/10.1016/j.lungcan.2013.07.022 |
| remote_bool |
true |
| author2 |
Kijima, Takashi Hamaguchi, Masanari Nakatani, Takeshi Koba, Taro Takahashi, Ryo Takeuchi, Yoshiko Kida, Hiroshi Nagatomo, Izumi Yamamoto, Suguru Tachibana, Isao Komuta, Kiyoshi Kawase, Ichiro |
| author2Str |
Kijima, Takashi Hamaguchi, Masanari Nakatani, Takeshi Koba, Taro Takahashi, Ryo Takeuchi, Yoshiko Kida, Hiroshi Nagatomo, Izumi Yamamoto, Suguru Tachibana, Isao Komuta, Kiyoshi Kawase, Ichiro |
| ppnlink |
ELV002331438 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.lungcan.2013.07.022 |
| up_date |
2024-07-06T20:22:59.938Z |
| _version_ |
1803862545465868288 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021754268</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623162119.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.lungcan.2013.07.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013006000003.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021754268</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0169-5002(13)00331-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Minami, Seigo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Erlotinib and pemetrexed have been approved for the second-line and maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended doses determined by our previous phase I study, we conducted a phase II study to evaluate the efficacy and safety of combination of the two agents in pretreated non-squamous NSCLC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second-line chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Erlotinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidermal growth factor receptor (EGFR) mutation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-squamous non-small cell cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase II</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pemetrexed</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kijima, Takashi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamaguchi, Masanari</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakatani, Takeshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koba, Taro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takahashi, Ryo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takeuchi, Yoshiko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kida, Hiroshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagatomo, Izumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamamoto, Suguru</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tachibana, Isao</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Komuta, Kiyoshi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawase, Ichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Garrote, Pedro J. ELSEVIER</subfield><subfield code="t">Extrinsic factors rather than seed traits mediate strong spatial variation in seed predation</subfield><subfield code="d">2019</subfield><subfield code="d">journal of the International Association for the Study of Lung Cancer</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002331438</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:82</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:271-275</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.lungcan.2013.07.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">82</subfield><subfield code="j">2013</subfield><subfield code="e">2</subfield><subfield code="h">271-275</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401602 |